C3 Antibody - #DF13224

Figure 7 Astrocyte activation in L2/3 level in SPARC-null mice. (A–C) Immunofluorescence staining of GFAP with PCNA, C3, and S100A10. The expression of the astrocyte marker GFAP (green) was increased both in white and gray matter in SPARC-null mice compared with WT mice, PCNA, C3, and S100A10 (red) were significantly increased in SPARC-null mice. Scale bars: 500 µm in spinal cord overall view, 20 µm in gray and white matter. (D) Western blot and quantitative analysis of C3, S100A10, IL-10, and TGF-β (normalized to β-actin). Data are shown as mean ± SD (n = 3 mice in each group). **P < 0.01, ***P < 0.001 (Student’s t-test). C3: Complement component 3; GFAP: glial fibrillary acidic protein; IL-10: interleukin-10; PCNA: proliferating cell nuclear antigen; S100A10: soluble protein-100α10; SPARC: secreted protein, acidic and rich in cysteine; TGF-β: transforming growth factor-beta; WT: wild-type.

Figure 7 Astrocyte activation in L2/3 level in SPARC-null mice. (A–C) Immunofluorescence staining of GFAP with PCNA, C3, and S100A10. The expression of the astrocyte marker GFAP (green) was increased both in white and gray matter in SPARC-null mice compared with WT mice, PCNA, C3, and S100A10 (red) were significantly increased in SPARC-null mice. Scale bars: 500 µm in spinal cord overall view, 20 µm in gray and white matter. (D) Western blot and quantitative analysis of C3, S100A10, IL-10, and TGF-β (normalized to β-actin). Data are shown as mean ± SD (n = 3 mice in each group). **P < 0.01, ***P < 0.001 (Student’s t-test). C3: Complement component 3; GFAP: glial fibrillary acidic protein; IL-10: interleukin-10; PCNA: proliferating cell nuclear antigen; S100A10: soluble protein-100α10; SPARC: secreted protein, acidic and rich in cysteine; TGF-β: transforming growth factor-beta; WT: wild-type.

Figure 4 Effect of TSA on the spinal astrocytic activation. Representative immunofluorescence staining images (A) and quantitative analysis (B) for GFAP and CFB in the spinal cord. Scale bar, 20 μm. Representative western blot bands (C) and quantitative analysis (D) of GFAP, C3 and CFB proteins in the spinal cord. Data were presented as mean ± SD (n=3). *P

Fig. 2. Astrocytes were activated as the A1 phenotype in spinal cord. (A–E) The spinal expression of GFAP, C3 and Serping1 were significantly increased in spinal cord at 14 d and 21 d after intraperitoneal injection of paclitaxel, while the spinal S100A10 and PTX3 were decreased at 14 d and 21 d (*p < 0.05, **p < 0.01, ***p < 0.001 compared with the vehicle group, n=6 in each group). (F–G) Dual-label immunofluorescence showed that A1 astrocytes markers (C3, Serping1) and A2 astrocytes markers (S100A10, PTX3) were mostly colocalized with GFAP in the dorsal horn of spinal cord. Scale Bar: 50 μm and 100 μm, respectively (n=4). The white arrow indicated typical co-staining cells.

Fig. 2. Astrocytes were activated as the A1 phenotype in spinal cord. (A–E) The spinal expression of GFAP, C3 and Serping1 were significantly increased in spinal cord at 14 d and 21 d after intraperitoneal injection of paclitaxel, while the spinal S100A10 and PTX3 were decreased at 14 d and 21 d (*p < 0.05, **p < 0.01, ***p < 0.001 compared with the vehicle group, n=6 in each group). (F–G) Dual-label immunofluorescence showed that A1 astrocytes markers (C3, Serping1) and A2 astrocytes markers (S100A10, PTX3) were mostly colocalized with GFAP in the dorsal horn of spinal cord. Scale Bar: 50 μm and 100 μm, respectively (n=4). The white arrow indicated typical co-staining cells.